{"organizations": [], "uuid": "011b1afee917f82598c1bdc0f6dc4dc942fb0add", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180427.html", "section_title": "Archive News &amp; Video for Friday, 27 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biophytis-presents-positive-macune/brief-biophytis-presents-positive-macuneos-preclinical-study-results-clinical-studies-to-follow-idUSFWN1S41TK", "country": "US", "domain_rank": 408, "title": "BRIEF-Biophytis Presents Positive Macuneos Preclinical Study Results, Clinical Studies To Follow", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-04-28T00:18:00.000+03:00", "replies_count": 0, "uuid": "011b1afee917f82598c1bdc0f6dc4dc942fb0add"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biophytis-presents-positive-macune/brief-biophytis-presents-positive-macuneos-preclinical-study-results-clinical-studies-to-follow-idUSFWN1S41TK", "ord_in_thread": 0, "title": "BRIEF-Biophytis Presents Positive Macuneos Preclinical Study Results, Clinical Studies To Follow", "locations": [], "entities": {"persons": [{"name": "biophytis", "sentiment": "negative"}], "locations": [{"name": "france", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "amd", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 27 (Reuters) - BIOPHYTIS SA:\n* MACUNEOS WAS SHOWN TO SIGNIFICANTLY SLOW LOSS OF VISUAL FUNCTION IN PRECLINICAL MODEL OF DRY AMD\n* MACA-PK CLINICAL STUDY IS EXPECTED TO START IN SECOND HALF OF 2018\n* RESULTS CONFIRMING POTENTIAL OF MACUNEOS DRUG CANDIDATE IN TREATMENT OF INTERMEDIATE DRY FORM OF AMD\n* TO OBTAIN FIRST CLINICAL DATA OF MACA-PK PHASE 1/2A STUDY IN PATIENTS WITH AMD IN H1 2019\n* SAD PHASE WILL BE CONDUCTED IN SECOND HALF OF 2018 * MACA-INTEREST PHASE 2B CLINICAL TRIAL AUTHORIZATION APPLICATIONS ARE EXPECTED TO BE FILED IN FRANCE AND UNITED STATES IN SECOND HALF OF 2019\n* RESULTS OF THE MACA-INTEREST CLINICAL STUDY ARE EXPECTED AT THE END OF 2022\n* SECOND MAD PHASE SECOND MAD PHASE (MULTIPLE ASCENDING DOSES) WILL BE CONDUCTED IN 2019\n* RECRUITMENT FOR MACA-INTEREST STUDY SHOULD START AT THE END OF THE FIRST HALF OF 2020\n* MACA-OBS MULTICENTRIC OBSERVATIONAL CLINICAL STUDY IS EXPECTED TO START IN THE SECOND HALF OF 2018\n* MACUNEOS IS THE ONLY DRUG CANDIDATE IN CLINICAL DEVELOPMENT TO TREAT DRY AMD Source text: bit.ly/2FmwEo0 Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://bit.ly/2FmwEo0", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-28T00:18:00.000+03:00", "crawled": "2018-04-28T12:49:11.010+03:00", "highlightTitle": ""}